Global Anti-Anemic Drug Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Anemia Type (Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, Others), By Route Of Administration (Oral, Injection), And By Geography - Forecasts From 2022 To 2027

The global anti-anemic drug market is projected to grow at a CAGR of 4.57% to reach US$18.830 billion by 2027, from US$13.770 billion in 2020.

An anti-anemia drug is used to cure anemia. Anemia is a condition in which there is a low number of red blood cells in a patient. Having low anemia can result in multiple organ failures due to a lack of oxygen being provided to them. Symptoms of anaemia are fatigue or pain. Females and adolescents with long-term diseases are more likely to have anaemia. Anaemia can be caused by blood loss, decreased or faulty red blood cell production, and the destruction of red blood cells. The anti-anemic drug is used to solve these issues in patients.

The global anti-anemia drug market is growing due to the increasing number of anemic patients and the growing geriatric population.

According to World Bank data, the global ageing population (people aged 65 and above) has increased from 7.49% of the total population of the world in the year 2009 to 8.87% of the total world population in the year 2018. The increase in the number of elderly people aged 65 and above is due to improved health facilities around the world and people living a better lifestyle that includes better food quality and other facilities required for living. The improvement in medication and drugs is also a factor for the geriatric population. This is further increasing the demand for anti-anaemia drugs.

Factors such as the increase in road accidents, rising cases of cancer, induced stress, poor nutritional habits, diabetes, rise in lactating, etc., are increasing the demand for anti-anemic drugs across the world. The government’s efforts to curb anemia by spreading awareness by launching a health campaign and providing medicines to poor people at low cost are further contributing to the market growth of anti-anemic drugs during the forecast period.

The global anti-anemic drug market is segmented by anemia type, route of administration, and geography. On the basis of anemia type, the market is segmented as iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia, pernicious anemia, and others. The market segmentation based on the route of administration is done as oral and injection.

Growing Anemia prevalence around the world is the major factor

The increasing prevalence of anaemia is increasing the demand for anti-anemic drugs. According to the World Health Organization (WHO), 39.8% of children aged 6-59 months were affected by anemia globally in 2019. The increasing unhealthy lifestyle, a high number of women of reproductive age, and complications during pregnancy, mostly in developing countries, are the factor for the increasing demand for anti-anaemic drugs. According to World Bank data, the prevalence of anemia among pregnant women was 36.5% in 2019. This increasing percentage of anemia among pregnant women is an alarming factor. Furthermore, the prevalence of anemia among children under 5 was 44.2% in 2005, reduced to 41.4% in 2014, and rose again to 41.7% in 2016. This increase in anaemia in children under 5 is due to non-healthy food habits and poverty in most of the developing countries in the world.

By geography, Asia Pacific has a significant share of the market

Regionally, the global anti-anemic drug market is classified into North America, South America, Europe, the Middle East and Africa (MEA), and Asia Pacific (APAC). The Asia Pacific anti-anemic drug market is expected to have a significant share in the global anti-anemia drug market due to the high prevalence of anaemia patients in the region. The increase in government expenditure on healthcare facilities and increasing health awareness among people is driving the anti-anemia drug market in the Asia Pacific region.

The increasing advancement in technology and the growing pharmaceutical industry in the Asia Pacific region are projected to further contribute to the growing anti-anemic drug market across the region. North America and Europe hold notable market shares in the global anti-anemic drug market due to the presence of large pharmaceutical companies and high health awareness among people in the region. The increasing research and development in the pharmaceutical industry will further bolster the market growth of anti-anemia drugs across these regions during the forecast period.

Key Developments

• March 2022: The Indian-based Zydus Life Sciences firm received approval from DCGI (Drugs Controller General of India) for the launch of its new offering, Oxemia, in the country. The new small ant-anemic oral drug Oxemia, an inhibitor of the HIF-PH enzyme, was developed to treat anaemia in patients suffering from Chronic Kidney diseases.
• February 2022: Agios Pharmaceuticals Inc., a pioneer in cellular metabolism and therapies, received US FDA approval for the launch of PYRUKYND in the treatment of hemolytic anemia in patients with pyruvate kinase deficiency. This drug is the first-ever medication that received approval for the treatment of pyruvate kinase deficiency.
• July 2019: GSK Pharmaceuticals opened a new manufacturing facility in Singapore. GSK has invested S$130 million to expand one facility and build two new facilities. According to the firm, the anti-anemic drug for treating CKD, Daprodustat, would be manufactured first in the manufacturing facility. 
• December 2019: FibroGen submitted a new drug application to the U.S. FDA for Roxadusat in patients with anaemia of Chronic Kidney Disease in both non-dialysis-dependent (NDD) and dialysis-dependent (D.D.) CKD patients. It is the first orally administered small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor submitted for FDA regulatory approval for the treatment of anaemia in CKD.
• November 2019: Acceleron got its new medicine REBLOZYL® (luspatercept-aamt) approved by the FDA. It is for treating anemia in adults with Beta-Thalassemia. It is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for patients who require regular Red Blood Cell transfusions.
• November 2019: Global Blood Therapeutics, Inc. got FDA approval for its Oxbryta™ (Voxelotor). It is the first medicine that specifically targets the root cause of Sickle Cell disease in adults and children 12 years of age or older.
• September 2019: Evrenzo (Roxadustat) Tablets for chronic kidney disease in dialysis patients were approved by the Ministry of Health, Labour and Welfare (MHLW) of Japan. It is the first orally administered inhibitor of hypoxia-inducible factor (HIF) prolyl-hydroxylase that corrects anemia by a mechanism of action that is different from that of erythropoiesis-stimulating agents (ESAs).

COVID-19 Insights

COVID-19 had a negative impact on the global anti-anemic drug market. The mandated lockdown and social distancing measures enforced by the government to contain the virus resulted in the partial closure of multiple production facilities, cooling down the market growth. Furthermore, the closure of ports, halt in airlines, and border restrictions across multiple countries further negatively impacted the market growth.

Global Anti-Anemic Drug Market Scope:

Segmentation

• By Anemia Type
  • Iron Deficiency Anemia
  • Sickle Cell Anemia
  • Aplastic Anemia
  • Hemolytic Anemia
  • Pernicious Anemia
  • Others
• By Route of Administration
  • Oral
  • Injection
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Indonesia
    • Thailand
    • Others

Frequently Asked Questions (FAQs)

Q1. What are the growth prospects for the anti-anemic drug market?
A1. The anti-anemic drug market is projected to grow at a CAGR of 4.57% during the forecast period.

Q2. What will be the anti-anemic drug market size by 2027?
A2. The global anti-anemic drug market is projected to reach a market size of US$18.830 billion by 2027.

Q3. What is the size of the global anti-anemic drug market?
A3. Anti-Anemic Drug Market was valued at US$13.770 billion in 2020. 

Q4. What factors are anticipated to drive the global anti-anemic drug market growth?
A4. The global anti-anemic drug market is growing due to the increasing number of anaemic patients and the growing geriatric population.

Q5. Which region holds the maximum market share of the anti-anemic drug market?
A5. The Asia Pacific region is expected to have a significant share in the global anti-anaemic drug market due to the high prevalence of anemia patients in the region.